Biodesix Inc
$ 13.02
1.96%
24 Feb - close price
- Market Cap 104,160,000 USD
- Current Price $ 13.02
- High / Low $ 13.30 / 11.95
- Stock P/E N/A
- Book Value -0.22
- EPS -5.23
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.21 %
- ROE -3.03 %
- 52 Week High 19.13
- 52 Week Low 3.44
About
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company is headquartered in Boulder, Colorado.
Analyst Target Price
$32.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-08-07 | 2025-05-06 | 2025-02-27 | 2024-11-05 | 2024-08-07 | 2024-05-08 | 2024-03-01 | 2023-11-07 | 2023-08-07 | 2023-05-11 | 2023-03-06 |
| Reported EPS | -1.16 | -0.08 | -0.08 | -0.06 | -0.07 | -0.08 | -0.14 | -0.1 | -0.14 | -0.17 | -0.24 | -0.35 |
| Estimated EPS | -0.0593 | -0.07 | -0.07 | -0.0667 | -0.07 | -0.09 | -0.14 | -0.11 | -0.15 | -0.21 | -0.24 | -0.28 |
| Surprise | -1.1007 | -0.01 | -0.01 | 0.0067 | 0 | 0.01 | 0 | 0.01 | 0.01 | 0.04 | 0 | -0.07 |
| Surprise Percentage | -1856.1551% | -14.2857% | -14.2857% | 10.045% | 0% | 11.1111% | 0% | 9.0909% | 6.6667% | 19.0476% | 0% | -25% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -1.05 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BDSX
2026-02-24 02:21:27
Biodesix (NASDAQ:BDSX) CEO Scott Hutton recently sold 1,490 shares of the company's stock for approximately $19,042, reducing his ownership by 2.96%. This transaction follows previous insider sales in February and January. Analysts currently rate Biodesix as a "Moderate Buy" with a consensus price target of $32.50, while institutional ownership stands at around 21%.
2026-02-24 02:07:27
Robin Harper Cowie, CFO of Biodesix (NASDAQ:BDSX), sold 535 shares of the company's common stock for approximately $6,834 on February 23, 2026. This transaction occurred after Cowie also exercised options to acquire 1,469 shares via restricted stock units on February 20, 2026. The sale comes as Biodesix shares have seen an 87.79% year-to-date surge, despite the company remaining unprofitable in the last twelve months, though recent preliminary Q4 and full-year 2025 results show significant revenue growth and EBITDA profitability.
2026-02-23 20:31:00
Biodesix Chief Development Officer Gary Anthony Pestano sold 556 shares of BDSX common stock for $7103 on February 23, 2026, at an average price of $12.7756 per share. This transaction occurred near the stock's InvestingPro Fair Value of $13.12, following his acquisition of 1528 shares through restricted stock unit exercise on February 20. The company recently reported strong preliminary financial results for Q4 and full year 2025, exceeding guidance and achieving EBITDA profitability.
2026-02-22 13:02:56
Telemark Asset Management LLC significantly reduced its stake in Biodesix, Inc. (NASDAQ:BDSX) by 95.0% in Q3, selling over 7.8 million shares and retaining 414,124 shares. Despite this large reduction by one fund, corporate insiders have been active with both sales and purchases, and institutional ownership remains at nearly 21%. Analysts generally maintain a "Moderate Buy" consensus with a $32.50 target price for Biodesix.
2026-02-21 12:43:35
Biodesix is a life sciences diagnostics company that specializes in personalized diagnostics for patient care, particularly in lung nodule and lung cancer testing. The company offers a range of services including development, biopharma, and life sciences services, utilizing multi-omic expertise and state-of-the-art laboratory technologies. Biodesix has seen significant growth, with strong financial results reported for 2025, and maintains strategic partnerships to advance its diagnostic solutions.
2026-02-19 08:57:46
Biodesix (NASDAQ:BDSX) is expected to announce its Q4 2025 earnings on Thursday, February 26th, with analysts projecting a loss of ($1.05) per share and revenue of $26.25 million. The stock currently holds a "Moderate Buy" rating from Wall Street with an average target price of $32.50. Recent insider activity shows CEO Scott Hutton selling shares, while Director Jack W. Schuler significantly increased his holdings, bringing total insider ownership to 30.10%.
